Drugs moving into the clinic: 24
The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
| Sponsor | Name | Indication | Mechanism |
|---|---|---|---|
| Genta & Emisphere Technologies | G4544 | Oncology - cancer-related hyper- calcemia that is resistant to hydration | oral formulation of Ganite (gallium nitrate injection) - directly inhibit calcium release from bone |
| OncoGenex Technologies | OGX-427 | Oncology - breast, ovarian, bladder, prostate or lung cancer | blocks production of Heat Shock Protein 27 (Hsp27), a cell-survival protein that inhibits apoptotic cell death through multiple pathways |
| Array BioPharma | ARRY-380 | Oncology - breast cancer | Her-2 (ErbB-2) kinase receptor inhibitor |
| Pharmasset & Roche | R7128 | Anti-infectives and Vaccines - hepatitis C virus (HCV) | Nucleoside polymerase inhibitor - trial now completed enrollment |
| OncoGenex | OGX-427 | Oncology - breast, ovarian, bladder, prostate or lung cancer | Blocks production of heat shock protein 27 (Hsp27), a cell-survival protein that inhibits apoptotic cell death through multiple pathways. |
| Pfizer & Kosan Biosciences | PF- 04548043 (formerly KOS-2187) | gastro-oesophageal reflux disease (GORD or GERD with US spelling) | Erythromycin derivative that activates motilin receptor (a GPCR) to stimulate gastrointestinal movement |
| CuraGen & Amgen Fremont (formerly Abgenix), using technology licensed from Seattle Genetics | CR011-vcMMAE | Oncology - unresectable Stage III or IV metastatic melanoma | Antibody-drug conjugate: Auristatin E (vcMMAE), a potent chemo- therapeutic linked to CR011 antibody, which targets GPNMB, a protein located specifically on the surface of melanoma cells |
| Vical | Vaxfectin- formulated pandemic influenza DNA vaccine | Anti-infectives and Vaccines - influenza | Investigational New Drug (IND) application accepted |
| Exelixis | XL518 | Oncology | specific inhibitor of MEK |
| Exelixis | XL228 | Oncology | dual inhibitor of IGF1R and wild-type and mutant forms of ABL including the imatinib and dasatinib resistant T315I mutant form of ABL |
| Exelixis | XL281 | Oncology | specific inhibitor of RAF |
| Exelixis | XL844 | Oncology | dual inhibitor of CHK1/2, in combination with gemcitabine |
| LymphoSign (now acquired by Aegera Therapeutics) | LS104 | Oncology - acute myelogenous leukemia and other myelo- proliferative disorders | Small molecule tyrosine kinase inhibitor |
